TY - JOUR
T1 - Three biomarkers (HER2, PD-L1, and microsatellite status) in a large cohort of metastatic gastroesophageal adenocarcinomas
T2 - The MD Anderson Cancer Center experience
AU - Sewastjanow-Silva, Matheus
AU - Kwiatkowski, Evan
AU - Yamashita, Kohei
AU - Abdelhakeem, Ahmed
AU - Yoshimura, Katsuhiro
AU - Vicentini, Ernesto R.
AU - Pizzi, Melissa P.
AU - Jin, Jiankang
AU - Fan, Yibo
AU - Zou, Gengyi
AU - Wang, Lingzhi
AU - Yin, Feng
AU - Dhar, Shilpa S.
AU - Blum Murphy, Mariela
AU - Mares, Jeannette E.
AU - Li, Jenny J.
AU - Gan, Qiong
AU - Waters, Rebecca E.
AU - Rogers, Jane E.
AU - Ajani, Jaffer A.
N1 - Publisher Copyright:
© 2024 UICC.
PY - 2024/12/15
Y1 - 2024/12/15
N2 - Human epidermal growth factor receptor-2 (HER2), programmed death-ligand 1 (PD-L1), and microsatellite (MS) status are well-established biomarkers in gastroesophageal adenocarcinomas (GEAs). However, it is unclear how the combination of these biomarkers is associated with clinicopathological factors and prognosis. This retrospective study included baseline metastatic GEA patients who were tested for all three biomarkers (HER2, PD-L1, and MS status) at the MD Anderson Cancer Center between 2012 and 2022. Stratification was performed according to the combination of biomarker profiles: triple negative (TN), single positive (SP), and multiple positive (MP). Comparative analyses of clinicopathological factors and survival using combinations of biomarkers were performed. Among the 698 GEA patients analyzed, 251 (36.0%) were classified as TN, 334 (47.9%) as SP, and 113 (16.1%) as MP. The MP group showed a significant association with tumors located in the esophagus (p <.001), well to moderate differentiation (p <.001), and the absence of signet ring cells (p <.001). In the survival analysis, MP group had a significantly longer overall survival (OS) compared to the other groups (MP vs. TN, p <.001 and MP vs. SP, p <.001). Multivariate Cox regression analysis revealed that MP serves as an independent positive prognostic indicator for OS (hazard ratio = 0.63, p <.01). Our findings indicate that MP biomarkers are associated with a favorable prognosis in metastatic GEA. These results are reflective of clinical practice and offer valuable insights into how therapeutics and future biomarkers could influence therapy/prognosis.
AB - Human epidermal growth factor receptor-2 (HER2), programmed death-ligand 1 (PD-L1), and microsatellite (MS) status are well-established biomarkers in gastroesophageal adenocarcinomas (GEAs). However, it is unclear how the combination of these biomarkers is associated with clinicopathological factors and prognosis. This retrospective study included baseline metastatic GEA patients who were tested for all three biomarkers (HER2, PD-L1, and MS status) at the MD Anderson Cancer Center between 2012 and 2022. Stratification was performed according to the combination of biomarker profiles: triple negative (TN), single positive (SP), and multiple positive (MP). Comparative analyses of clinicopathological factors and survival using combinations of biomarkers were performed. Among the 698 GEA patients analyzed, 251 (36.0%) were classified as TN, 334 (47.9%) as SP, and 113 (16.1%) as MP. The MP group showed a significant association with tumors located in the esophagus (p <.001), well to moderate differentiation (p <.001), and the absence of signet ring cells (p <.001). In the survival analysis, MP group had a significantly longer overall survival (OS) compared to the other groups (MP vs. TN, p <.001 and MP vs. SP, p <.001). Multivariate Cox regression analysis revealed that MP serves as an independent positive prognostic indicator for OS (hazard ratio = 0.63, p <.01). Our findings indicate that MP biomarkers are associated with a favorable prognosis in metastatic GEA. These results are reflective of clinical practice and offer valuable insights into how therapeutics and future biomarkers could influence therapy/prognosis.
KW - adenocarcinoma
KW - biomarkers
KW - gastroesophageal
KW - multiple positive
KW - triple negative
UR - http://www.scopus.com/inward/record.url?scp=85198524476&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85198524476&partnerID=8YFLogxK
U2 - 10.1002/ijc.35090
DO - 10.1002/ijc.35090
M3 - Article
C2 - 38995150
AN - SCOPUS:85198524476
SN - 0020-7136
VL - 155
SP - 2277
EP - 2286
JO - International journal of cancer
JF - International journal of cancer
IS - 12
ER -